By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Recce Ltd  

Level 34, 50 Bridge Street
AMP Centre
Sydney  New South Wales  2000  Australia
Phone: 61-2-8216-0768 Fax:


Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.




Founder: Graham JH Melrose

CFO: Peter Williams


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Recce
Symbol: RCE


Company News
Recce (RCE) Confirms Pre-IND Data Submission To U.S. FDA For Its Lead Antibiotic Candidate 9/7/2017 9:51:11 AM
Recce (RCE) Confirms Delivery By Intravenous Drip For Its RECCE 327 Antibiotic, With FDA IND Submission On Track 7/31/2017 8:39:34 AM
Recce (RCE) Achieves Milestone With Volume Production Of Antibiotic Compounds To Support Clinical Trials 7/20/2017 9:00:51 AM
Recce (RCE) Constructs Automated Manufacturing Facility To Support Clinical Trials 6/22/2017 9:42:05 AM
Recce (RCE) Secures Up To A$6.05 Million Investment Agreement With US Institutional Investor 6/16/2017 8:33:14 AM
Recce (RCE) Moves Closer To Clinical Study Application With Additional Data On Its Novel Antibiotic 5/19/2017 9:13:53 AM
Recce (RCE) Operational Update 4/10/2017 7:59:02 AM
Recce (RCE) Release: Pharma’s Lead Compound Reduces Illness In Mice Infected By Resistant E. Coli Bacteria 1/18/2017 9:25:10 AM